Filing Details
- Accession Number:
- 0001140361-12-035019
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-08-03 15:10:30
- Reporting Period:
- 2012-08-01
- Filing Date:
- 2012-08-03
- Accepted Time:
- 2012-08-03 15:10:30
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1184149 | W Jonathan Ayers | One Idexx Drive Westbrook ME 04092 | Chairman, President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-08-01 | 20,000 | $0.00 | 356,686 | No | 4 | M | Direct | |
Common Stock | Disposition | 2012-08-01 | 14,800 | $88.06 | 341,886 | No | 4 | S | Direct | |
Common Stock | Disposition | 2012-08-01 | 200 | $88.61 | 341,686 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2012-08-01 | 20,000 | $0.00 | 20,000 | $38.34 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
37,392 | 2013-02-13 | No | 4 | M | Direct |
Footnotes
- The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/27/2012.
- The sale price reported reflects the weighted average price of multiple transactions on the reported date at prices that ranged from $87.57 to $88.51, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $88.58 to $88.63, inclusive.
- Grant of options to buy shares of common stock becomes exercisable as to 12,000 shares on 02/14/2007, 02/14/2008, 02/14/2009, 02/14/2010, and the remaining 9,392 shares on 02/14/2011.